We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In an Israeli trial, severely ill patients treated with Bonus BioGroup's stem-cell based product MesenCure showed significant improvement, reported Globes.